Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “For President, Director and Chief Medical Officer of MyMD. tumor necrosis factor receptor I (TNFRI) and IL-6.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 5, 2022

“This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Joint Blog

JULY 25, 2020

organic food market by 2025 is at $70.4 The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To It has been predicted that the U.S CBD Products and the FDA The U.S.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

DECEMBER 23, 2021

billion by 2025. However, no single cannabinoid drug has received widespread approval in the treatment of pain. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

SpeedWeed

MARCH 19, 2021

Worldwide, there are nearly 50 million people living with Alzheimer’s Disease (AD) today, and that number is predicted to increase by 14 percent or more by 2025. AD is now the 6th leading cause of death in the US, but there is no treatment on the market that can prevent, cure, or even slow the spread of this disease.

CBD 52

CBD Clinical Trials Treatment Therapy 52

Cannabis Law Report

JULY 15, 2022

Last week, federal Health Minister Greg Hunt announced changes to regulations that would allow for medicinal cannabis exports, capitalising on what the Government estimated would be a $70 billion industry by 2025. Different strains for different conditions. Different strains are grown to treat different medical conditions.

Medicine 52

Medicine Patients Media Supply Chain 52